Ultragenyx Pharmaceutical Inc.
RARE
$34.72
-$0.68-1.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -549.58M | -569.18M | -558.99M | -585.12M | -613.35M |
| Total Depreciation and Amortization | 35.69M | 35.54M | 34.68M | 33.12M | 29.62M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 110.65M | 105.53M | 101.25M | 106.09M | 107.83M |
| Change in Net Operating Assets | 13.30M | 13.92M | 4.47M | -23.56M | -32.76M |
| Cash from Operations | -389.94M | -414.19M | -418.59M | -469.47M | -508.67M |
| Capital Expenditure | -5.60M | -7.49M | -8.44M | -10.52M | -22.44M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 13.29M | -10.28M | -219.08M | 122.79M | 173.58M |
| Cash from Investing | 7.69M | -17.77M | -227.52M | 112.28M | 151.13M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 392.40M | 392.24M | 719.67M | 740.73M | 388.17M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 7.06M | 7.00M | 7.00M | 0.00 | 636.00K |
| Cash from Financing | 399.46M | 399.24M | 726.67M | 740.73M | 388.81M |
| Foreign Exchange rate Adjustments | -398.00K | -2.53M | 1.05M | -940.00K | -428.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16.81M | -35.24M | 81.61M | 382.59M | 30.84M |